TVARDI THERAPEUTICS, INC. Inventory Write-down
TVARDI THERAPEUTICS, INC. (TVRD) reported Inventory Write-down of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2025-05-13
- TVARDI THERAPEUTICS, INC. inventory write-down for the quarter ending 2025-03-31 was $0.00.
- TVARDI THERAPEUTICS, INC. inventory write-down for the quarter ending 2024-12-31 was $454.00K.
- TVARDI THERAPEUTICS, INC. inventory write-down for the quarter ending 2024-09-30 was $1.02M.
- TVARDI THERAPEUTICS, INC. inventory write-down for the quarter ending 2024-06-30 was $1.49M.
- TVARDI THERAPEUTICS, INC. inventory write-down for fiscal 2024 was $2.96M, a 463.31% increase from fiscal 2023.
- TVARDI THERAPEUTICS, INC. inventory write-down for fiscal 2023 was $526.00K, a 1447.06% increase from fiscal 2022.
- TVARDI THERAPEUTICS, INC. inventory write-down for fiscal 2022 was $34.00K.
- TVARDI THERAPEUTICS, INC. inventory write-down for fiscal 2021 was $0.00.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $454.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.47M derived: sum of 3 quarters · filed 2025-05-13 | $2.96M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | $454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.47M derived: sum of 2 quarters · filed 2025-03-11 | $2.96M derived: sum of 3 quarters · filed 2025-03-11 | $2.96M 10-K · filed 2025-03-11 |
| 2024-09-30 | $1.02M 10-Q · filed 2024-11-14 | $2.51M derived: sum of 2 quarters · filed 2024-11-14 | $2.51M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $1.49M 10-Q · filed 2024-08-14 | $1.49M 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $526.00K 10-K · filed 2024-03-06 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $34.00K derived: sum of 2 quarters · filed 2024-05-13 | $34.00K derived: sum of 3 quarters · filed 2024-05-13 | $34.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $34.00K derived: sum of 2 quarters · filed 2024-03-06 | $34.00K derived: sum of 3 quarters · filed 2024-03-06 | $34.00K 10-K · filed 2024-03-06 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |